Literature DB >> 6389126

A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.

G B Calandra, M Hesney, C Grad.   

Abstract

The efficacy, safety and tolerance of imipenem/cilastatin and moxalactam were compared in a randomized trial in the United States involving 19 centers and 441 patients. Significantly more organisms were susceptible to imipenem than moxalactam. Although the bacteriological outcomes were similar, the clinical outcome was significantly better in the imipenem/cilastatin treatment group. The incidence of colonization and superinfection was similar in both groups. Moxalactam was less irritating at the site of injection than imipenem/cilastatin. The safety profiles were similar except for bleeding episodes in the moxalactam group.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6389126     DOI： 10.1007/bf02017380

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


  11 in total

1.  N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.

Authors:  J J Lipsky
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

2.  Acute colitis related to penicillin and penicillin derivatives.

Authors:  R B Toffler; E G Pingoud; M I Burrell
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

3.  Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin.

Authors:  G B Calandra; F M Ricci; C Wang; K R Brown
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

4.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.

Authors: 
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

6.  Imipenem versus moxalactam in the treatment of serious infections.

Authors:  L J Eron; D L Hixon; C H Park; R I Goldenberg; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

7.  Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin.

Authors:  R L Marier; R V McCloskey; G Dickenson; C V Sanders; K E Aldridge; T Hoffman; D Gutterman; A Janney
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

8.  Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.

Authors:  J C Wade; C R Smith; B G Petty; J J Lipsky; G Conrad; J Ellner; P S Lietman
Journal:  Lancet       Date:  1978-09-16       Impact factor: 79.321

9.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Moxalactam in the therapy of serious infections.

Authors:  R L Marier; S Faro; C V Sanders; W Williams; F Derks; A Janney; K Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191
View more
  12 in total

1.  Imipenem: a new carbapenem. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors: 
Journal:  CMAJ       Date:  1988-09-15       Impact factor: 8.262

2.  Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.

Authors:  H Lode; R Wiley; G Höffken; J Wagner; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Emergence of resistance to imipenem in Pseudomonas aeruginosa.

Authors:  M J Lynch; G L Drusano; H L Mobley
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Imipenem-cilastatin as initial therapy for febrile cancer patients.

Authors:  G P Bodey; M E Alvarez; P G Jones; K V Rolston; L Steelhammer; V Fainstein
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 7.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

8.  Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.

Authors:  K Sack; J Herhahn; R Marre; E Schulz
Journal:  Infection       Date:  1985       Impact factor: 3.553

9.  Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors:  L J Eron; L Harvey; D L Hixon; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

10.  Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections.

Authors:  R R MacGregor; G A Gibson; J A Bland
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.